Tag: PTX

Prescient Therapeutics ASX PTX OmniCAR CAR-T cell Therapy cancer

Prescient Therapeutics unveils new data validating cancer cell therapy technology

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonstrates the capability of its OmniCAR cell therapy technology in killing multiple cancer cells. The...
Prescient Therapeutics ASX PTX brain cancer Donald M O’Rourke

Prescient Therapeutics appoints leading brain cancer specialist to advisory board

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer specialist Professor Donald O’Rourke to its scientific advisory board. Professor O’Rourke has considerab...
Prescient Therapeutics ASX PTX cancer 2021 PTX-100 PTX-200 OmniCAR CAR-T

After ‘tremendous’ FY 2021, Prescient Therapeutics well-funded to advance cancer-fighting therapies

Clinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable it to advance its multiple cancer programs, with work to follow on from what managing director Steve...
Prescient Therapeutics ASX PTX raises fund cancer treatment pipeline

Prescient Therapeutics raises $7 million to fund cancer treatment pipeline

Biotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pipeline of innovative cancer treatments. The clinical stage oncology company today announced it has...
Prescient Therapeutics ASX PTX Peter MacCallum Cancer Centre

Prescient Therapeutics teams up with Peter MacCallum Cancer Centre to advance CAR-T cancer therapy

Prescient Therapeutics (ASX: PTX) has moved closer to developing its unique CAR-T cancer technology after revealing a collaboration with the world-renowned Peter MacCallum Cancer Centre (Peter Mac) in...
Prescient Therapeutics ASX PTX Peter Doherty Institute for Infection and Immunology COVID-19

Prescient Therapeutics assets chosen for COVID-19 antiviral test program

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets have been selected as group one priority candidates for a COVID-19 antiviral testing program in Melbour...
Prescient Therapeutics ASX PTX University of Pennsylvania Oxford University OmniCAR cancer

Prescient Therapeutics obtains two key licences to develop ‘chimeric immune receptor platform’ OmniCAR

Biotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil two significant licences related to its universal immune receptor technology platform, currently in...
Prescient Therapeutics ASX PTX clinical oncology cancer basket trial

Prescient Therapeutics proceeds to next stage of PTX-100 drug trial for patients with advanced cancers

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has confirmed a phase 1b basket study of its cancer drug PTX-100 will proceed to the next dose level following successful completion o...
Prescient Therapeutics breast cancer women PTX ASX Phase 2 HER2 negative

Prescient Therapeutics receives encouraging efficacy results for leading cancer drug candidate PTX-200

Oncology company Prescient Therapeutics (ASX: PTX) has unveiled news of a high response rate to its PTX-200 leading drug candidate from a phase 2 breast cancer trial. The news comes less than two w...
Prescient Therapeutics ASX PTX interim data phase 1b ovarian cancer trial

Prescient Therapeutics confirms positive early results in drug trial for patients with platinum-resistant ovarian cancer

Oncology specialist company Prescient Therapeutics (ASX: PTX) has announced positive interim data from a phase 1b safety study of its lead drug PTX-200 in women with recurrent or persistent platinum-r...
Prescient Therapeutics ASX PTX study eradicating cancer patients acute myeloid leukemia AML

Prescient Therapeutics expands study after completely eradicating cancer in patients

Cancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients with acute myeloid leukemia (AML) after three patients were completely eradicated of the disease. ...
Prescient Therapeutics ASX PTX Carina Biotech Chimeric Antigen Receptor T-cell cancer solid tumour

Prescient Therapeutics and Carina Biotech to develop CAR-T cell solid tumour therapies

Oncology company Prescient Therapeutics (ASX: PTX) has unveiled a potentially lucrative collaboration with Adelaide-based Carina Biotech to develop new Chimeric Antigen Receptor T-cell (CAR-T) targete...
Prescient Therapeutics ASX PTX lead drug candidate PTX-200 oncology breast cancer

Prescient Therapeutics maintains positive development for lead breast cancer drug candidate

Oncology company Prescient Therapeutics (ASX: PTX) has delivered some positive interim news relating to its study evaluating the impact of its lead drug candidate PTX-200 on locally advanced breast ca...
Prescient Therapeutics ASX PTX US drug cancer oncology PTX-200 inhibitors ovarian breast leukaemia

Prescient Therapeutics teams up with US oncology counterpart to expand cancer drug portfolio

Oncology specialist Prescient Therapeutics (ASX: PTX) has said it intends to expand its product development pipeline by commencing a collaboration with an as yet unnamed “leading private US-based drug...
Prescient Therapeutics ASX PTX breast cancer clinical trial

Prescient Therapeutics clinical trial sees two sufferers eradicate breast cancer

Prescient Therapeutics’ (ASX: PTX) clinical trial of its PTX-200 drug in breast cancer patients taking the chemotherapy drug paclitaxel has doubled the overall response rate to 50% and eradicated canc...